Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6068846 | 1.00 | MAP3K14 (0.35) | MAP3K14HTR7CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL17861392 | 0.73 | MAP3K14 (0.38) | MAP3K14MEN1KMT2A | |
| SCHEMBL6069296 | 0.73 | NISCH (0.39) | SLC6A2NISCH | |
| SCHEMBL2071541 | 0.73 | NISCH (0.39) | SLC6A2NISCH | |
| SCHEMBL2069021 | 0.73 | NISCH (0.39) | SLC6A2NISCH | |
| SCHEMBL19054489 | 0.71 | HTR7 (0.38) | MAP3K14HTR7CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL8291502 | 0.70 | MTNR1A (0.46) | MAP3K14CYP2D6MEN1KMT2A | |
| SCHEMBL7073528 | 0.68 | MAP3K14 (0.35) | MAP3K14 | |
| SCHEMBL21307339 | 0.68 | MAP3K14 (0.35) | MAP3K14HTR7CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL6068629 | 0.68 | CYP19A1 (0.35) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109234-B2 | Benzoxathiepine derivatives and their use as medicines | PIERRE FABRE MEDICAMENT (FR) | 2006-09-19 | — | — | US | disclosed |
| EP-1370547-B1 | BENZOAXATHIEPIN DERIVATIVES AND THEIR USE AS MEDICINES | PF MEDICAMENT (FR) | 2004-09-15 | — | — | EP | disclosed |
| US-20040127552-A1 | Benzoaxathiepin derivatives and their use as medicines | PIERRE FABRE MEDICAMENT (FR) | 2004-07-01 | — | — | US | disclosed |
| EP-1370547-A1 | BENZOAXATHIEPIN DERIVATIVES AND THEIR USE AS MEDICINES | PIERRE FABRE MEDICAMENT (FR) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002081464-A1 | BENZOAXATHIEPIN DERIVATIVES AND THEIR USE AS MEDICINES | PIERRE FABRE MEDICAMENT (FR) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127552-A1 | Benzoaxathiepin derivatives and their use as medicines | CYP4A11, CYP3A4, CYP4F11 | MAP3K14 2111/4885HTR7 312/4885CYP2D6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.